RENAL ANAEMIA: RECENT DEVELOPMENTS AND FUTURE DIRECTIONS FOR IMPROVED MANAGEMENT

被引:1
作者
Mahon, A. [1 ]
Bennett, L. [2 ]
机构
[1] Barts & London NHS Trust, London, England
[2] Oxford Kidney Unit, Oxford, England
关键词
Anaemia; Chronic kidney disease; Erythropoiesis-stimulating agents; Haemoglobin;
D O I
10.1111/j.1755-6686.2007.tb00054.x
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The global burden of chronic kidney disease (CKD) and associated anaemia is substantial. With the increasing numbers of patients that are likely to be affected in the future, approaches are required to improve anaemia management without increasing the workload of renal units. Advocating early treatment may improve patient outcomes and nurses are in an ideal position to identify and manage anaemia at an early stage in patients with CKD. In addition, adopting a multidisciplinary approach, alongside nephrologists, diabetologists, cardiologists, social workers, nutritionists and pharmacists, may allow nurses to detect and treat anaemia earlier in patients with CKD. Maintaining awareness of factors associated with decreased erythropoiesis-stimulating agents (ESAs) efficacy (e.g. iron deficiency or poor nutritional status) is also important. To reduce the burden on healthcare providers, anaemia management could be simplified by extending the administration interval of ESAs. Recent studies have explored the clinical efficacy of administration of currently available agents at intervals of up to once monthly in highly selected, stable patients. The use of an ESA that can control anaemia while maintaining haemoglobin levels within guideline ranges with extended administration intervals in all patients without the need for additional screening or stepwise dose adjustments with attendant monitoring may help improve patient care while reducing the workload of healthcare providers.
引用
收藏
页码:108 / 114
页数:7
相关论文
共 40 条
  • [1] Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
    Besarab, Anatole
    Salifu, Moro O.
    Lunde, N. Martin
    Bansal, Vinod
    Fishbane, Steven
    Dougherty, Frank C.
    Beyer, Ulrich
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (04) : 626 - 639
  • [2] The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes
    Boven, K
    Stryker, S
    Knight, J
    Thomas, A
    van Regenmortel, M
    Kemeny, DM
    Power, D
    Rossert, J
    Casadevall, NE
    [J]. KIDNEY INTERNATIONAL, 2005, 67 (06) : 2346 - 2353
  • [3] Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin
    Casadevall, N
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 : 37 - 41
  • [4] Collins AJ, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1058
  • [5] Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey
    Coresh, J
    Astor, BC
    Greene, T
    Eknoyan, G
    Levey, AS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (01) : 1 - 12
  • [6] The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes
    Curtis, BM
    Ravani, P
    Malberti, F
    Kennett, F
    Taylor, PA
    Djurdjev, O
    Levin, A
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (01) : 147 - 154
  • [7] Assessing provider time for anaemia management of dialysis patients using time & motion methods: A multi-centre observational study in Europe
    De Cock, E
    Van Bellinghen, L
    Standaert, B
    [J]. VALUE IN HEALTH, 2002, 5 (06) : 581 - 581
  • [8] Identifying patients with chronic kidney disease from general practice computer records
    de Lusignan, S
    Chan, T
    Stevens, P
    O'Donoghue, D
    Hague, N
    Dzregah, B
    Van Vlymen, J
    Walker, M
    Hilton, S
    [J]. FAMILY PRACTICE, 2005, 22 (03) : 234 - 241
  • [9] Chronic kidney disease: the global challenge
    El Nahas, AM
    Bello, AK
    [J]. LANCET, 2005, 365 (9456) : 331 - 340
  • [10] Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin
    Fishbane, S
    Berns, JS
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (03) : 1337 - 1343